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Screening for Asymptomatic Bacteriuria in Adults
US Preventive Services Task Force
Recommendation Statement
US Preventive Services Task Force
IMPORTANCE Among the general adult population, women (across all ages) have the highest
prevalence of asymptomatic bacteriuria, although rates increase with age among bothmen
and women. Asymptomatic bacteriuria is present in an estimated 1% to 6% of
premenopausal women and an estimated 2% to 10% of pregnant women and is associated
with pyelonephritis, one of themost common nonobstetric reasons for hospitalization in
pregnant women. Among pregnant persons, pyelonephritis is associated with perinatal
complications including septicemia, respiratory distress, low birth weight, and spontaneous
preterm birth.
OBJECTIVE To update its 2008 recommendation, the USPSTF commissioned a review of the
evidence on potential benefits and harms of screening for and treatment of asymptomatic
bacteriuria in adults, including pregnant persons.
POPULATION This recommendation applies to community-dwelling adults 18 years and older
and pregnant persons of any age without signs and symptoms of a urinary tract infection.
EVIDENCE ASSESSMENT Based on a review of the evidence, the USPSTF concludes with
moderate certainty that screening for and treatment of asymptomatic bacteriuria in pregnant
persons has moderate net benefit in reducing perinatal complications. There is adequate
evidence that pyelonephritis in pregnancy is associated with negative maternal outcomes
and that treatment of screen-detected asymptomatic bacteriuria can reduce the incidence of
pyelonephritis in pregnant persons. The USPSTF found adequate evidence of harms
associated with treatment of asymptomatic bacteriuria (including adverse effects of
antibiotic treatment and changes in themicrobiome) to be at least small in magnitude.
The USPSTF concludes with moderate certainty that screening for and treatment of
asymptomatic bacteriuria in nonpregnant adults has no net benefit. The known harms
associated with treatment include adverse effects of antibiotic use and changes to the
microbiome. Based on these known harms, the USPSTF determined the overall harms to be
at least small in this group.
RECOMMENDATIONS The USPSTF recommends screening pregnant persons for asymptomatic
bacteriuria using urine culture. (B recommendation) The USPSTF
recommends against screening for asymptomatic bacteriuria in nonpregnant adults.
(D recommendation)
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Summary of Recommendations
Asymptomatic bacteriuria is defined as the presence of bacteria
in the urine of a person without signs or symptoms of a urinary
tract infection.1 Among the general adult population, women
(across all ages) have the highest prevalence of asymptomatic
bacteriuria, although rates increase with age among both men
and women.2 The reported prevalence of asymptomatic bacteri-
uria ranges from 1% to 6% among premenopausal women to 22%
among women older than 90 years.3,4 Asymptomatic bacteriuria
is present in an estimated 2% to 10% of pregnant women.5 The
condition is rare in men.4,6
During pregnancy, physiologic changes that affect the urinary
tract increase the risk of asymptomatic bacteriuria and sympto-
maticurinarytract infections, includingpyelonephritis (aurinarytract
infection in which one or both kidneys become infected).7 Pyelo-
nephritis is one of themost commonnonobstetric reasons for hos-
pitalization in pregnant women.8 Pyelonephritis is associatedwith
perinatal complications including septicemia, respiratory distress,
low birth weight, and spontaneous preterm birth.9
Thepresenceof asymptomaticbacteriuria hasnotbeen shown
to increase the risk of adverse health outcomes among nonpreg-
nant persons.6,10
USPSTF Assessment of Magnitude of Net Benefit
Pregnant Persons
TheUSPSTF concludedwithmoderate certainty that screening for
and treatmentof asymptomaticbacteriuria inpregnantpersonshas
moderate net benefit in reducing perinatal complications (Figure
and Table; see the eFigure in the Supplement for explanation of
USPSTF grades and levels of evidence). There is adequate evi-
dence that pyelonephritis in pregnancy is associatedwith negative
maternal outcomes and that treatment of screen-detected asymp-
tomatic bacteriuria can reduce the incidence of pyelonephritis in
pregnant persons. However, evidence shows that the incidence of
pyelonephritis amongpregnantwomenwithuntreatedasymptom-
atic bacteriuria has been low in recent decades, whichmay reduce
thepotentialbenefit fromscreeningasymptomaticbacteriuria.When
direct evidence is limited, absent, or restricted to select popula-
tions or clinical scenarios, theUSPSTFmay place conceptual upper
or lower bounds on themagnitude of benefit or harms. Therefore,
theUSPSTFbounds thebenefitsof screening forasymptomaticbac-
teriuria in pregnant persons as no greater thanmoderate.
TheUSPSTF found inadequatedirect evidenceon theharmsof
screeningforasymptomaticbacteriuria inpregnantpersons,although
these harms are thought to be no greater than small inmagnitude.
TheUSPSTFfoundadequateevidenceofharmsassociatedwithtreat-
ment of asymptomatic bacteriuria, including adverse effects of an-
tibiotic treatment. It alsoconsideredthepotential effectsof changes
in the microbiome resulting from antibiotic use. Therefore, the
USPSTF bounds the overall magnitude of harms of screening for
asymptomatic bacteriuria in pregnant persons to be at least small.
Nonpregnant Adults
The USPSTF concludes with moderate certainty that screening for
and treatment of asymptomatic bacteriuria in nonpregnant adults
The USPSTF recommends screening for asymptomatic
bacteriuria using urine culture in pregnant persons.
The USPSTF recommends against screening for asymptomatic
bacteriuria in nonpregnant adults.
B recommendation
D recommendation
See the Figure for a more detailed
summary of the recommendation
for clinicians.
Figure. Clinician Summary for Screening for Asymptomatic Bacteriuria in Adults
What does the USPSTF
recommend?
For pregnant persons: Grade B
To whom does this
recommendation apply?
What’s new?
How to implement this
recommendation?
The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize
decision-making to the specific patient or situation.
This applies to adults 18 years and older and pregnant persons of any age without signs and symptoms of a urinary tract infection.
It does not apply to persons who have chronic medical or urinary tract conditions or are hospitalized or living in institutions
such as nursing homes.
This recommendation is consistent with the 2008 USPSTF recommendation. The USPSTF continues to recommend screening
for pregnant persons and recommends against screening for nonpregnant adults.
Screen. Screen pregnant persons for asymptomatic bacteriuria using a midstream, clean-catch urine culture at the first
prenatal visit or at 12 to 16 weeks of gestation, whichever is earlier. A urine culture showing >100 000 CFU/mL of a single
uropathogen or >10 000 CFU/mL if the pathogen is group B streptococcus indicates treatment.
Screen persons who are pregnant for asymptomatic bacteriuria with a urine culture.
For nonpregnant adults: Grade D
Do not screen adults who are not pregnant for asymptomatic bacteriuria.
September 2019
CFU indicates colony-forming units; USPSTF, US Preventive Services Task Force.
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has no net benefit (Table). There is adequate evidence that treat-
ment of screen-detected asymptomatic bacteriuria in nonpreg-
nant adults has no benefit. Based on the harms associatedwith an-
tibiotic use, the USPSTF found adequate evidence to bound the
harms of treatment of screen-detected asymptomatic bacteriuria
in nonpregnant adults as at least small.
Practice Considerations
Patient Population Under Consideration
This recommendationapplies to adults 18years andolder andpreg-
nant persons of any age without signs and symptoms of a urinary
tract infection(Figure). Itdoesnotapply topersonswhohavechronic
medical or urinary tract conditions, such as end-stage renal dis-
ease;have indwellingurinarycatheters,urinarystents,or spinal cord
injuries;arehospitalized; reside inan institution(eg,anursinghome);
or who are transplant recipients.
Definition of Asymptomatic Bacteriuria
Asymptomatic bacteriuria occurs when the urinary tract is colo-
nizedwithsignificantamountsofpathogenicbacteria,primarily from
the gastrointestinal tract, in the absence of symptoms or signs of a
urinary tract infection. The most common pathogen is Escherichia
coli, althoughotherbacteria suchasKlebsiella,Proteusmirabilis, and
group B streptococcus can be involved.4,11
Assessment of Risk
The risk of developing asymptomatic bacteriuria varies by age, sex,
andpregnancy status.6Becauseof the locationand lengthof the fe-
male urethra, women are predisposed to infections of the urinary
tract, including asymptomatic bacteriuria.5 Physiologic changes in
both pregnant and olderwomen increase the risk of asymptomatic
bacteriuria and a urinary tract infection.7,11,12 In general, men are at
low risk of developing asymptomatic bacteriuria, although rates in-
creasewith older age.12 Personswith diabetes are also at increased
risk of developing asymptomatic bacteriuria.4,6
Screening Tests
Screening for asymptomatic bacteriuria during pregnancy is done
with a urine culture at 12 to 16weeks of gestation or at the first pre-
natal visit. Urine culture is currently recommended for screening in
pregnancy and is the established method for diagnosis.2 A culture
obtainedusing amidstream, clean-catch urine samplewith greater
than 100000 colony-forming units (CFU) per milliliter of a single
uropathogen is considered a positive test result.6 Greater than
10000CFU/mL of group B streptococcus is an indicator of vaginal
colonization and is commonly used as the threshold for treatment
of infection in pregnancy.13
Screening Intervals
In general, screening is performedonceat the first prenatal visit per
clinical guidelines. However, there is little evidence on the optimal
timing and frequency of screening for asymptomatic bacteriuria in
pregnancy.2
Treatment or Interventions
Pregnantpersonswithasymptomaticbacteriuriausually receivean-
tibiotic therapy, based on urine culture results and follow-upmoni-
toring. The choiceof antibacterial regimen for treatment of asymp-
tomaticbacteriuriaduringpregnancy isbasedonsafety inpregnancy
and patterns of antimicrobial resistance in the particular setting.6,7
Update of Previous USPSTF Recommendation
In this update, the USPSTF continues to recommend screening for
asymptomaticbacteriuria inpregnantpersonswithurinecultureand
recommendsagainst screening innonpregnant adults. TheUSPSTF
changed the grade for pregnant persons from an “A” to a “B” based
on the reduced applicability of the previous evidence that included
outdated antibiotic treatment regimens and newer evidence that
shows a significantly lower risk of pyelonephritis than found in pre-
vious reviews. In addition, there are newer concerns about antibi-
oticuse, suchasantimicrobial resistanceandadversechanges to the
microbiome (not addressed in current studies), leading to an in-
crease in the magnitude of potential harms. These factors led the
USPSTF to reduce assessments of certainty andmagnitude of ben-
efit, resulting in the change of grade.
Since 1996, the USPSTF has maintained an “A” recommenda-
tion for 1-timescreening forasymptomaticbacteriuriawithurinecul-
ture inpregnantpersonsbetween 12and 16weeksofgestation.The
Table. Summary of USPSTF Rationale
Pregnant Persons Nonpregnant Adults
Detection Urine culture is the established method for detecting asymptomatic bacteriuria.
Benefits of
screening and
treatment
• There is inadequate direct evidence that screening for asymptomatic bacteriuria
improves health outcomes.
• There is adequate evidence that treatment of screen-detected asymptomatic
bacteriuria reduces the incidence of pyelonephritis, a serious condition in
pregnancy. However, given the lower prevalence of pyelonephritis found in more
recent studies, the overall benefits can be bounded as no greater than moderate
in magnitude.
• There is inadequate direct evidence that screening for
asymptomatic bacteriuria improves health outcomes.
• There is adequate evidence that treatment of
screen-detected asymptomatic bacteriuria has
no benefit.
Harms of
screening and
treatment
• There is inadequate direct evidence to determine the harms of screening though
they can be bounded to be no greater than small in magnitude.
• There is adequate evidence that the overall harms of treatment can be bounded
as at least small in magnitude. This is based on the direct evidence of harms,
such as side effects of antibiotic treatment, and the indirect evidence of harms
associated with antibiotic use.
There is inadequate direct evidence to determine the
harms of screening and treatment. However, based on the
known harms associated with antibiotic use, the overall
harms can be bounded as at least small in magnitude.
USPSTF
assessment
The USPSTF concludes with moderate certainty that screening for and treatment of
asymptomatic bacteriuria in pregnant persons has a moderate net benefit.
The USPSTF concludes with moderate certainty that
screening for and treatment of asymptomatic bacteriuria
in nonpregnant adults has no benefit and may be harmful.
See eFigure in the Supplement for explanation of US Preventive Services Task Force (USPSTF) grades and levels of evidence.
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original 1996 recommendation was reaffirmed in 2004 and again
in 2008.14-16 In 1996, theUSPSTF found that therewas insufficient
evidence to recommend for or against screening in older adult
women or women with diabetes and, in a separate recommenda-
tion, that screeningwas not recommended in other asymptomatic
adults or older adults who reside in an institution.14 In 2004, these
recommendations were combined into a single recommendation
against screening,whichwas subsequently reaffirmed in2008.15,16
Supporting Evidence
Scope of Review
TheUSPSTF commissioned a systematic evidence review to evalu-
ate the evidence on the potential benefits and harms of screening
for and treatment of asymptomatic bacteriuria in community-
dwellingadults, includingpregnantpersons.2,17This reviewwasused
to update the 2008 USPSTF recommendation statement.16
Evidence on Benefits of Screening and Treatment
Pregnant Persons
Twoobservational cohort studiesconducted inSpainandTurkeybe-
tween 1987 and 199918,19 (n = 5289) examined outcomes in
screened and unscreened pregnantwomen. Both studies included
patients screened at the first prenatal visit with urine culture and
treated on detection of asymptomatic bacteriuria. In both studies,
few cases of pyelonephritis developed in women in either cohort.
Only oneof the studies reported additional outcomes, including in-
fant birthweight, prematurity, intrauterine death, and intrauterine
growth restriction, although the study was not adequately pow-
ered to detect differences in these outcomes.2,18
Twelve trials of pregnant women (n = 2377) screened for
asymptomatic bacteriuria and randomized to either a treatment or
control condition (placebo or no treatment) were included in the
review.20-31 Most studies were conducted in hospital-based
obstetrics-gynecology clinics. Seven studies reported screening at
the first prenatal visit, 2 studies reported the specific gestational
age at which screeningwas performed, and 3 studies did not report
the timing of screening.2 All but 2 studies were published in the
1960s or 1970s, with themost recent studies published in 1987 and
2015.25,31 In the older studies, there was sparse reporting on many
patient characteristics such as age and race/ethnicity. In addition,
treatment regimens for screen-detected asymptomatic bacteriuria
varied according to themedication used, timing, duration, and dos-
age. Antibiotics were used in all studies except 1, although several
antibiotics tested in the trials are no longer recommended for treat-
ment of urinary tract infections in pregnancy.2 Rates of pyelone-
phritis in the control groups were considerably higher in the 10
older studies than in the 2 more recent ones (7% to 36% vs 2.2%
and 2.5%, respectively). Lower rates of pyelonephritis in newer
studies suggests that themagnitude of benefit from screeningmay
be reduced relative to screening in earlier cohorts.
Patients in the control groups had higher rates of pyelonephri-
tis than those in the treatment groups in all but one of the
studies.25 Pooled analysis demonstrated a 76% reduction in pyelo-
nephritis among the intervention groups (pooled relative risk [RR],
0.24 [95% CI, 0.14-0.40]; 12 studies; n = 2068).2 A sensitivity
analysis that removed studies deemed to have high risk of bias
demonstrated a similar risk reduction (pooled RR, 0.19 [95% CI,
0.11-0.34]; 7 studies; n = 1184).2
Seven treatment studies reportedon the incidenceof lowbirth
weight. The pooled analysis found statistically significant reduc-
tions in the incidence of infants with low birth weight (pooled RR,
0.64 [95%CI, 0.46-0.90]; 7 studies; n = 1522).2 Pretermbirth and
perinatal mortality were reported in 3 and 6 studies, respectively.
For both outcomes, results were mixed and pooled estimates did
not demonstrate statistical significance.
Nonpregnant Adults
No studies were identified that directly evaluated the benefits
of screening for asymptomatic bacteriuria in the general adult
population. Five trials (n = 777)32-36 addressed the benefits of
treatment of screen-detected asymptomatic bacteriuria in general
adult populations. All 5 studies included participants who had 2
consecutive positive screening urine cultures using a midstream,
clean-catch urine sample and using a cutoff of greater than
100000 CFU/mL. Across all studies, 84% to 100% of participants
were women. One study included women aged 20 to 65 years
without diabetes, 1 study included only women with diabetes
(mean age, 55 years), and 3 studies included only older patients liv-
ing in independent living facilities. In general, characteristics of par-
ticipants were sparsely reported across studies, with none report-
ing on race/ethnicity. Treatment varied across trials, ranging from a
single dose to 3 months of antibiotics. No study found a difference
in the rates of symptomatic infections ormortality between treated
and untreated groups.2
Evidence on Harms of Screening and Treatment
Pregnant Persons
One cohort study (n = 186) that compared screened and un-
screened pregnant women reported on potential harms (congeni-
tal abnormalities) associated with the screening program, with no
meaningful differences reported.18
Seven studies reportedonharms associatedwith treatment of
screen-detectedasymptomaticbacteriuria.20,22-24,28,29,31 Fivestud-
ies (n = 961) reported on congenital malformations. All but 1 study
reported fewer cases in the intervention group, although the num-
ber of cases was small and pooled estimates were not statistically
significant.2 Other infant or fetal harms, such as jaundice (2 stud-
ies), respiratorydistress (1 study), andneonatal sepsis (1 study)were
sparsely reported and event rates were low, which limited
comparisons.2 Adverse reactions to medications were reported in
2studies; vaginitis anddiarrheawereassociatedwithampicillin, and
nausea and rashes were reported with use of nalidixic acid and
nitrofurantoin.2 Complications of pregnancy and delivery (such as
third-trimester hemorrhage, premature rupture of the mem-
branes, nonspontaneous onset of labor, or cesarean delivery be-
fore onset of labor)were inconsistently and sparsely reported, lim-
iting any conclusions.2
Nonpregnant Adults
Two studies of treatment in nonpregnant women34,36 and 2 stud-
ies in older adults32,35 reported on rates of adverse events associ-
ated with treatment of asymptomatic bacteriuria. Overall, harms
were not reported consistently, which limited the conclusions that
could be drawn from the current evidence base.
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Nostudieswere identified that addressed theharmsof screen-
ing for asymptomatic bacteriuria in nonpregnant adults.
HowDoes Evidence FitWith Biological Understanding?
The relationship between asymptomatic bacteriuria and adverse
pregnancy outcomes is related to a combination of factors.
Women are at increased risk of urinary tract infections, including
asymptomatic bacteriuria, because of the anatomical placement
of the urethra.2 Conditions such as increased blood glucose levels
and urinary stasis (in which the bladder is unable to completely
empty) can increase risk for symptomatic urinary tract infections
and pyelonephritis. Pregnancy further increases the risk because
of changes in urine pH, bladder compression, and urethral
dilation.37 Pyelonephritis in pregnancy has been associated with
worse pregnancy outcomes.9,37,38 Screening for and treatment of
asymptomatic bacteriuria in pregnant persons could prevent
cases of pyelonephritis and associated negative pregnancy out-
comes.
Antibiotics are the mainstay treatment for urinary tract infec-
tions, but there are consequences to their use. The use of antibiot-
ics is known to lead to antimicrobial resistance. In addition, there is
emerging evidence that bacterial colonization of the gastrointesti-
nal and genitourinary tracts plays a protective role. Antibiotic use
can disrupt these effects.
Response to Public Comment
A draft version of this recommendation statement was posted for
public comment on the USPSTF website from April 23 through
May 20, 2019. Commenters requested more information about
how the USPSTF assessed older evidence. The USPSTF recog-
nizes that older studies have certain limitations. However, in
reviewing all available evidence on the benefits and harms of
treating screen-detected asymptomatic bacteriuria in pregnant
women, the USPSTF found the evidence to be adequate. Several
comments sought clarification on the USPSTF’s rationale for
changing the grade of the recommendation from an “A” to a “B”
for pregnant persons. A change in grade may occur when evi-
dence has increased or decreased and results in a change in the
certainty or magnitude of net benefit.39 Newer evidence, such as
the lower prevalence of pyelonephritis and a better understand-
ing of the harms associated with antibiotic use, changed the USP-
STF’s assessment of both the certainty (from high to moderate
certainty) and net benefit of screening (from substantial to mod-
erate net benefit), leading to the grade change.
Research Needs and Gaps
TheUSPSTF identified several gaps in the evidencewheremore re-
search is needed:
• Therewerefewstudiesthatexaminedasymptomaticbacteriuriaand
risk of serious outcomes (ie, pyelonephritis or urosepsis) inmodern
pregnant populations. Epidemiologic evidence suggests that the
prevalence of asymptomatic bacteriuria has been low in recent de-
cades, andmany antibiotics used in older studies are no longer rec-
ommendedforuse inpregnancy.Moreobservational studiesexam-
ining thiswouldhelp improve theapplicabilityof theevidencebase.
• Clinical trials,observational studies, andnatural experiments inset-
tingswhereasymptomaticbacteriuria screeningandtreatmentare
not the standard of care or where guidelines are changing would
be useful in assessing benefits and harms.
• Newerunderstandingsof thehumanmicrobiomesuggest thatbac-
terial colonizationmay play a protective role in bothmothers and
babies. For pregnant and nonpregnant populations, research is
needed to better understand the microbiology of a healthy uri-
nary tract and the natural history of asymptomatic bacteriuria.
• The role of current patterns of antibiotic use in the epidemiology
ofasymptomaticbacteriuria isunclear.Antibioticuse increases the
risk of antimicrobial resistance and can change the microbiome.
More research is needed to better understand potential harms of
treatment and theeffects of antibiotic useonnewborn, child, and
longer-term health.
Recommendations of Others
TheInfectiousDiseasesSocietyofAmericarecommendsscreeningfor
asymptomaticbacteriuria inpregnantwomenandtreatmentforthose
whoscreenpositive.40TheAmericanCollegeofObstetriciansandGy-
necologistsendorsesthe InfectiousDiseasesSocietyofAmerica’s rec-
ommendationsforscreeningforasymptomaticbacteriuria inpregnant
womenandtreatmentforthosewhoscreenpositive.TheCanadianTask
Force onPreventiveHealth Care recommends screening in pregnant
womenwithurinecultureonceduringthefirst trimester,althoughthis
wasissuedasa“weak”recommendationandthequalityofevidencewas
consideredlow.41TheAmericanAcademyofPediatrics(AAP)hasnospe-
cific recommendationtoscreenforasymptomaticbacteriuria inpreg-
nant persons. However, the AAP recommends that clinicians treat
pregnantpersonsandperformatestof cure if asymptomaticbacteri-
uria is found to be present on a urine culture. In 2008, the American
Academy of Family Physicians recommended screening in pregnant
womenat12to16weeksofgestationoratthefirstprenatalvisit,which-
ever comes first.42
The AAP, the American Academy of Family Physicians, and the
UnitedKingdom’sNational Institute forHealth andCareExcellence
all recommend against screening for and treatment of asymptom-
atic bacteriuria in nonpregnant adults.42-44 The American College
ofObstetricians andGynecologists recommends against screening
for and treatmentof asymptomaticbacteriuria innonpregnant,pre-
menopausal women.45
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